Skip to main content

Advertisement

SpringerLink
Log in

Standardized versus research-based PAM50 intrinsic subtyping of breast cancer

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  CAS  Google Scholar 

  2. Bastien RRL, Rodríguez-Lescure Á, Ebbert MTW, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics. 2012;5:44.

    Article  CAS  Google Scholar 

  3. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

    Article  Google Scholar 

  4. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869–74.

    Article  Google Scholar 

  5. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.

    Article  Google Scholar 

  6. Perou CM, Parker JS, Prat A, et al. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11:718–9.

    Article  Google Scholar 

  7. Pogue-Geile KL, Song N, Jeong J-H, et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 2015;33:1340–7.

    Article  CAS  Google Scholar 

  8. Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Nat Cancer Inst. 2014;107:2014.

    Google Scholar 

  9. Gendoo DMA, Ratanasirigulchai N, Schröder MS, et al. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics. 2015;32:1097–9.

    Article  Google Scholar 

  10. Turner NC, Liu Y, Zhu Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer. J Clin Oncol. 2019;37:1169.

    Article  CAS  Google Scholar 

  11. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–36.

    Article  CAS  Google Scholar 

  12. Prat A, Cheang MCU, Galván P, et al. Prognostic value of intrinsic subtypes in hormone receptor-positive metastatic breast cancer treated with letrozole with or without lapatiniblapatinib therapy and subtype in hormone receptor-positive metastatic breast cancerlapatinib therapy and subtype in hormone receptor-positive metastatic breast cancer. JAMA Oncol. 2016;2:1287–94.

    Article  Google Scholar 

  13. Prat A, Brase JC, Cheng Y, et al. Everolimus plus exemestane for hormone receptor‐positive advanced breast cancer: a PAM50 intrinsic subtype analysis of BOLERO‐2. Oncologist. 2019;24(7):893–900. https://doi.org/10.1634/theoncologist.2018-0407.

    Article  CAS  Google Scholar 

  14. Cejalvo JM, Martínez de Dueñas E, Galvan P, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017;77:2213–21.

    Article  CAS  Google Scholar 

  15. Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346.

    Article  CAS  Google Scholar 

  16. Prat A, Fan C, Fernández A, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med. 2015;13:303–303.

    Article  Google Scholar 

  17. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305:1873–81.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

    A. Prat

  2. Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain

    A. Prat

  3. SOLTI, Barcelona, Spain

    A. Prat

  4. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    J. S. Parker

  5. Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    J. S. Parker

Authors
  1. A. Prat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Prat.

Ethics declarations

Conflict of interest

AP reports consulting and lecture fees from Nanostring Technologies, Inc. JP disclosed that he is an inventor of the pending patents on which the Prosigna Assay is based and a paid consultant of NanoString Technologies, Inc.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prat, A., Parker, J.S. Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. Clin Transl Oncol 22, 953–955 (2020). https://doi.org/10.1007/s12094-019-02203-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02203-x

Search

Navigation